T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Triple-Negative Breast Cancer Clinical Trial

Official title:

An Open-label, Single-arm Phase II Trial of First-line Treatment With Trastuzumab Deruxtecan for Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer, Luminal Androgen Receptor Subtype With Low Human Epidermal Growth Factor Receptor 2 (HER2) Expression.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05953168
• Other study ID #: SCHBCC-N059
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 2023
• Est. completion date: August 2026

Study information

• Verified date: July 2023
• Source: Fudan University
• Contact: Zhimin Shao, MD, PhD
• Phone: +86-021-64175590
• Email: zhimingshao[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single-arm phase II trial of first-line treatment with trastuzumab deruxtecan (T-DXd) for patients with locally advanced or metastatic triple-negative breast cancer, luminal androgen receptor subtype (TNBC-LAR) with low HER2 expression.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 69
• Est. completion date: August 2026
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Women aged 18-70 years old;

2. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score 0 or 1;

3. Expected lifetime of not less than three months;

4. Disease-free interval >6 months;

5. Adequate tumor tissue samples collected within a time frame of less than 3 months;

6. Histological results recorded as TNBC [negative HER2, ER, and progesterone receptor (PgR) status] and LAR subtype according to the classification of Fudan University Shanghai Cancer Center (FUSCC);

7. Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1);

8. Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resected;

9. Adequate hematologic and end-organ function, laboratory test results;

10. Within the 3 weeks prior to study initiation, patients have not received radiotherapy, endocrine therapy, targeted therapy, or surgery, and have recovered from acute toxicities associated with previous treatments (if surgery was performed, wound healing is complete); no peripheral neuropathy or grade I peripheral neurotoxicity.

11. Female subjects with fertility are required to use a medically approved contraceptive method during the study treatment;

12. Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.

Exclusion Criteria:

1. Use of radiotherapy (except for palliative reasons), chemotherapy, and immunotherapy in the 3 weeks prior to treatment, excluding bisphosphonates (which can be used for bone metastasis);

2. History of clinically uncontrolled heart disease, including congestive heart failure, angina, myocardial infarction within the past 6 months, or ventricular arrhythmias;

3. Common Terminology Criteria for Adverse Events (CTCAE) grade =1 adverse reactions attributed to previous treatments;

4. Underwent major surgery (excluding outpatient minor procedures, such as placement of vascular access) within the first 3 weeks of the investigational treatment;

5. Pregnant or lactating patients;

6. History of malignancy within the past five years (excluding cured basal cell carcinoma and cervical carcinoma in situ);

7. Presence of third-space fluid accumulation (such as significant pleural effusion and ascites) that cannot be controlled by drainage or other methods;

8. Non-infectious interstitial lung disease (ILD) or non-infectious pneumonia requiring steroid hormone therapy, current ILD/non-infectious pneumonia, or suspected ILD/non-infectious pneumonia that cannot be ruled out by imaging examinations during screening (Note: Subjects found to have ILD/non-infectious pneumonia during baseline screening chest CT are ineligible);

9. Known active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection or HBV DNA =500, or patients with chronic phase accompanied by abnormal liver function;

10. Individuals with allergies or a history of known allergy to components of the study drugs or other monoclonal antibodies;

11. History of immunodeficiency, including HIV-positive test results, acquired or congenital immunodeficiency diseases, or history of organ transplantation. Positive syphilis antibody test;

12. According to the investigator's judgment, any evidence of diseases that the investigator considers unfavorable for the subject's participation in the study or that may affect their adherence to the protocol.

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Neoplasms
• Triple-Negative Breast Cancer

Intervention

Drug:
• Trastuzumab Deruxtecan
Trastuzumab Deruxtecan for TNBC-LAR patients with HER2 low expression

Locations

Country	Name	City	State
China	Breast cancer institute of Fudan University Cancer Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response of Complete Response (ORR)	Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 in all Participants	3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first)
Secondary	Duration of response (DOR)	Length of time that a tumor continues to respond to treatment without the cancer Duration of response is the time from response to progression/death	3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first)
Secondary	Disease Control Rate (DCR)	Proportion of all subjects receiving study therapy whose best overall response is complete response (CR), partial response (PR), and stable disease (SD) for 8 weeks or more according to RECIST v1.1 criteria.	3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first)
Secondary	Progression Free Survival (PFS)	Defined as the date from enrollment to the first recording of tumor progression (as measured by RECIST v1.1 criteria with or without continued treatment) or the date of death from any cause, whichever occurs first.	3 years (assessed at Screening, every 6 weeks for the first 12 months, thereafter every 9 weeks until disease progression or death, whichever occurs first)
Secondary	Overall Survival (OS)	Defined as the time from enrollment to the date of death from any cause.	Every 6 months